Real-world evidence on the use of hospital resources for subcutaneous and intravenous trastuzumab administration in breast cancer patients at a referral public hospital in Mexico [0.03%]
墨西哥一家转诊公立医院乳腺癌患者皮下和静脉注射曲妥单抗使用情况的真实世界证据研究
Tatiana Fiordelisio,Francisco Valdés-Souto,Diana Del-Rio Valdes et al.
Tatiana Fiordelisio et al.
Aim: The availability of subcutaneous (SC) trastuzumab has introduced a practical alternative to traditional intravenous (IV) delivery for HER2-positive breast cancer. Beyond clinical equivalence, the shift toward SC administration offers t...
Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma - Canadian perspective [0.03%]
复发/难治性弥漫大B细胞淋巴瘤患者的医疗资源使用情况（加拿大视角）
Kimberly Guinan,Mathieu Pelletier,Monika Ham et al.
Kimberly Guinan et al.
Aim: Epcoritamab, the first subcutaneous (SC) bispecific approved for relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL), offers potential advantages in terms of healthcare resource utilization (HCRU) associated with its SC admin...
Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis [0.03%]
网状meta分析：评估Elafibranor与Seladelpar作为原发性胆汁性胆管炎二线治疗相对于临床有效性和安全性的优劣
David Jones,Emily Combe,Harun Knight et al.
David Jones et al.
Aim: To indirectly compare the efficacy and safety of elafibranor and seladelpar, as second-line treatments for primary biliary cholangitis. Materials & methods: Bayesian network meta-analyses compared data from randomized-controlled studie...
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25 [0.03%]
一石二鸟：真实世界证据如何在卫生技术评估和报销中大展拳脚？第二部分
Paul Arora,Sreeram V Ramagopalan
Paul Arora
In this update, we discuss the use of real-world data in the Haute Autorité de Santé assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the ...
Readmissions and retreatment among stent-assisted endovascular coiling patients with unruptured intracranial aneurysm using ENTERPRISE® 2 stent versus LVIS™ stent [0.03%]
ENTERPRISE® 2支架与LVIS™支架辅助 coils治疗未破裂颅内动脉瘤再入院及再次治疗的回顾性分析
Reade De Leacy,Rahul Khanna,Emilie Kottenmeier et al.
Reade De Leacy et al.
Aim: The treatment of wide-necked unruptured intracranial aneurysms (UIA) remains clinically challenging. Stent-assisted coiling (SAC) is a commonly used treatment modality for UIAs. The objective of this study was to examine the difference...
Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD [0.03%]
EVOLVE研究的新进展：评估外用eteplirsen、golodirsen和casimersen治疗DMD的现实世界经验
Cuixia Tian,Shannon Grabich,Aravindhan Veerapandiyan et al.
Cuixia Tian et al.
Aim: Eteplirsen, golodirsen and casimersen are phosphorodiamidate morpholino oligomers (PMOs) that have received, based on biomarker data, accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patien...
Clinical outcomes of pressure-enabled drug delivery for trans-arterial chemoembolization and radioembolization [0.03%]
压力驱动给药在肝动脉化疗栓塞和放射性微球治疗中的临床疗效研究
Deepshekhar Gupta,Yunjuan Liu,Chris Miller-Rosales et al.
Deepshekhar Gupta et al.
Aim: Prior research observed that pressure-enabled drug delivery (PEDD) counteracts intra-tumoral pressure during trans-arterial chemoembolization (TACE) and radioembolization (TARE), improving drug penetration, yet real-world evidence rema...
Access in all areas? A round-up of developments in market access and health technology assessment: part 14 [0.03%]
无所不在的准入吗？市场准入和卫生技术评估的发展概述：第14部分
Sreeram V Ramagopalan,Annie Jullien Pannelay
Sreeram V Ramagopalan
In this update we examine the selection of 15 drugs for the third cycle of Medicare price negotiations under the Inflation Reduction Act and analyze emerging evidence of the Most-Favored-Nation impact on global pharmaceutical access, includ...
Comparative effectiveness of oral antibiotics to treat uncomplicated urinary tract infections in male outpatients [0.03%]
口服抗生素治疗门诊男性非复杂性泌尿道感染的效果比较研究
Karl Madaras-Kelly,Jeremy Boyd,Laura Bond
Karl Madaras-Kelly
Aim: New IDSA guidelines define uncomplicated UTI (uUTI) as infection limited to the bladder in both men and women. This study compared the effectiveness of β-lactams, nitrofurantoin and trimethoprim/sulfamethoxazole (TMP/SMX) to fluoroqui...
Ataluren for the treatment of people living with nonsense mutation Duchenne muscular dystrophy: a plain language summary of Study 041 [0.03%]
ataluren治疗染色体变异杜氏肌营养不良患者：研究041通俗版报告书
Shiwen Wu,Dmitry Vlodavets,Alexandra Prufer de Queiroz Campos Araujo et al.
Shiwen Wu et al.
What is this summary about?: This article describes results from Study 041. Study 041 was a clinical study of ataluren, a treatment for people living with nonsense mutation Duchenne muscular dystrophy (nmDMD for short). O...